Dr. Ostertag is a co-founder of Abintus and serves as Chief Scientific Officer. Dr. Ostertag has more than 20 years of virology, immunology, and gene therapy experience with a proven track record of taking gene and cell therapy technologies from start-up through BLA applications. This includes the integration of multiple disciplines spanning molecular virology, immunotherapy, retroviral-based gene therapy, bioinformatics and clinical biomarker, mechanism of action and safety assay development. He has multiple issued gene therapy related patents and strong publication record with demonstrated success in preclinical and clinical research programs to support regulatory filings, biomarker discovery, manufacturing, and clinical trials. Derek obtained his doctorate in Molecular Biology from the UC San Diego and San Diego State University, and was a post-doctoral researcher at the Burnham Institute for Medical Research, San Diego as an Arthritis Foundation Fellow.